321 related articles for article (PubMed ID: 28719592)
1. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.
Hsu PI; Tsai FW; Kao SS; Hsu WH; Cheng JS; Peng NJ; Tsai KW; Hu HM; Wang YK; Chuah SK; Chen A; Wu DC
Am J Gastroenterol; 2017 Sep; 112(9):1374-1381. PubMed ID: 28719592
[TBL] [Abstract][Full Text] [Related]
2. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.
Pabón-Carrasco M; Keco-Huerga A; Castro-Fernández M; Saracino IM; Fiorini G; Vaira D; Pérez-Aísa Á; Tepes B; Jonaitis L; Voynovan I; Lucendo AJ; Lanas Á; Martínez-Domínguez SJ; Almajano EA; Rodrigo L; Vologzanina L; Brglez Jurecic N; Denkovski M; Bujanda L; Abdulkhakov RA; Huguet JM; Fernández-Salazar L; Alcaide N; Velayos B; Silkanovna Sarsenbaeva A; Zaytsev O; Ilchishina T; Barrio J; Bakulin I; Perona M; Alekseenko S; Romano M; Gravina AG; Núñez Ó; Gómez Rodríguez BJ; Ledro-Cano D; Pellicano R; Bogomolov P; Domínguez-Cajal M; Almela P; Gomez-Camarero J; Bordin DS; Gasbarrini A; Kupčinskas J; Cano-Català A; Moreira L; Nyssen OP; Mégraud F; O'Morain C; Gisbert JP;
United European Gastroenterol J; 2024 Feb; 12(1):122-138. PubMed ID: 38050339
[TBL] [Abstract][Full Text] [Related]
3. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study.
Liu J; Ji CR; Li YY; Qiao C; Hu JN; Wan M; Lin MJ; Lin BS; Wang J; Zha J; Li LX; Zuo XL
Clin Transl Gastroenterol; 2021 Aug; 12(8):e00391. PubMed ID: 34397042
[TBL] [Abstract][Full Text] [Related]
4. Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial.
Huang Y; Chen J; Ding Z; Chen X; Liang X; Zeng X; Xu F; Han Y; Lu H
J Gastroenterol; 2023 Jul; 58(7):633-641. PubMed ID: 37042991
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial.
Alhalabi M; Alassi MW; Alaa Eddin K; Cheha K
BMC Infect Dis; 2021 Jul; 21(1):642. PubMed ID: 34218802
[TBL] [Abstract][Full Text] [Related]
6. 14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
Amiot A; Hacoon J; Heluwaert F; Mion F; Lamarque D; Moussata D; Mimouni M; Delchier JC; Durand-Zaleski I; Audureau E; Bastuji-Garin S;
Helicobacter; 2024; 29(2):e13076. PubMed ID: 38680067
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Tetracycline Three Times Daily was Comparable to That of Four Times Daily for Helicobacter pylori Rescue Treatment: A Multicenter, Noninferiority, Randomized Controlled Trial.
Han Z; Zhang Q; Mirza IA; Ding Y; Nan X; Zhao Q; Li R; Xu L; Zhang N; Duan M; Zeng S; Kong Q; Zhang W; Wang H; Wu X; Zuo X; Li Y; Li Y
Helicobacter; 2024; 29(3):e13102. PubMed ID: 38873902
[TBL] [Abstract][Full Text] [Related]
8. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Zhang D; Ke L; Ni Z; Chen Y; Zhang LH; Zhu SH; Li CJ; Shang L; Liang J; Shi YQ
Medicine (Baltimore); 2017 Aug; 96(32):e7697. PubMed ID: 28796053
[TBL] [Abstract][Full Text] [Related]
9. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
Kim YI; Lee JY; Kim CG; Park B; Park JY; Choi IJ
BMC Gastroenterol; 2021 Mar; 21(1):95. PubMed ID: 33653284
[TBL] [Abstract][Full Text] [Related]
10. Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial.
Oh CK; Lim H; Seo SI; Lee SP; Bang CS; Shin WG; Kim JB; Jang HJ; Baik GH
BMC Gastroenterol; 2023 Dec; 23(1):453. PubMed ID: 38129806
[TBL] [Abstract][Full Text] [Related]
11. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial.
Hsu PI; Chen KY; Tai WC; Yang JC; Tsay FW; Liu YH; Chen CL; Lee CL; Yeh HZ; Kuo CH; Chuah SK; Lee HC; Shie CB; Shiu SI; Kao JY; Yamaoka Y; Graham DY; Wu DC;
Am J Gastroenterol; 2023 Jul; 118(7):1184-1195. PubMed ID: 36940437
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
Kim MS; Kim N; Kim SE; Jo HJ; Shin CM; Park YS; Lee DH
BMC Gastroenterol; 2013 Sep; 13():138. PubMed ID: 24050512
[TBL] [Abstract][Full Text] [Related]
13. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
Yan TL; Wang JH; He XJ; Zhu YB; Lu LJ; Wang YJ; Wang ZW; Gao JG; Xu CF; Ma H; Luan SM; Li L; Chen Y
Am J Gastroenterol; 2024 Apr; 119(4):655-661. PubMed ID: 37975609
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of 7 days versus 10 days triple therapy based on levofloxacin-dexlansoprazole for eradication of
Elkhodary NM; Farrag KA; Elokaby AM; El-Hay Omran GA
Indian J Pharmacol; 2020; 52(5):356-364. PubMed ID: 33283766
[TBL] [Abstract][Full Text] [Related]
15. Second-line bismuth-containing quadruple therapy for
Kim SE; Park MI; Park SJ; Moon W; Kim JH; Jung K; Kim HK; Lee YD
World J Gastroenterol; 2017 Feb; 23(6):1059-1066. PubMed ID: 28246480
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Helicobacter pylori infection: current status and future concepts.
Yang JC; Lu CW; Lin CJ
World J Gastroenterol; 2014 May; 20(18):5283-93. PubMed ID: 24833858
[TBL] [Abstract][Full Text] [Related]
17. V Spanish Consensus Conference on Helicobacter pylori infection treatment.
Gisbert JP; Alcedo J; Amador J; Bujanda L; Calvet X; Castro-Fernández M; Fernández-Salazar L; Gené E; Lanas Á; Lucendo AJ; Molina-Infante J; Nyssen OP; Pérez-Aisa A; Puig I
Gastroenterol Hepatol; 2022 May; 45(5):392-417. PubMed ID: 34629204
[TBL] [Abstract][Full Text] [Related]
18. [Quadruple treatment with doxycycline, furazolidone, bismuth and proton pump inhibitor is still effective against Helicobacter pylori in our population].
Barreda-Costa CS; Piccini-Larco JR; Chu-Revollar LD; Salazar-Muente F; Barriga-Briceño JA; Herrera-Alzamora MA
Rev Gastroenterol Peru; 2023; 43(2):116-119. PubMed ID: 37597225
[TBL] [Abstract][Full Text] [Related]
19. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience.
Abd-Elsalam S; Kobtan A; El-Kalla F; Elkhalawany W; Nawasany SE; Saif SA; Yousef M; Ali LA; Soliman S; Mansour L; Habba E; Soliman H; Rizk F; Shehata MA
Medicine (Baltimore); 2016 Jun; 95(24):e3879. PubMed ID: 27310977
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy and drug safety comparison of one-week Vonoprazan triple therapy with two-weeks Esomeprazole triple therapy in Helicobacter pylori infection: Findings from a single-centre randomized clinical trial in population of Pakistan.
Waqar F; Noor M; Haider E; Farhat K; Ali S; Fatime Gilani SF
J Pak Med Assoc; 2024 Mar; 74(3):432-435. PubMed ID: 38591272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
